Friday 6 November 2026 Export ZTS’s income statement to Excel — free account

Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024.

Revenue: −0.24%
EPS: +2.48%
Free cash flow: +17.4%
Total debt: +37.5%

Quarter to June 2026, against a year earlier

81.72 7.48 −8.39%

Follow ZTS

Alert me

Market cap: $33.9B
P/E: 13.4×
Fwd P/E: 14.2×
Dividend yield: 2.59%
F-score: 7/9
Altman Z: 5.73
Beneish M: −2.45
Dividend safety: 88/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Zoetis Inc. 10-K filed Feb 13, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed Feb 13, 2025 · accepted 2:51 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov